Name: Latest research reports of Beta Drugs Ltd. authored by Edelweiss and published by - Trendlyne research reports.
Item: Beta Drugs Ltd.
Rating: 5
Author: Edelweiss

Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
08 Nov 2024	Beta Drugs	Edelweiss Target	1698.60	2245.00	2194.00 (-22.58%)	Target met	Buy	pdf post cache	Broker Report Beta Drugs \| H1FY25 Result Update Edelweiss Strong show in H1; near-term growth factored in pdf Copy Link Share on Share on Share on Share on Alert
16 May 2024	Beta Drugs	Edelweiss Target	1698.60	1600.00	1179.90 (43.96%)	Target met	Buy	pdf post cache	Broker Report Beta Drugs Ltd \| H2FY24 Result Update Edelweiss Deepening its roots in the market pdf Copy Link Share on Share on Share on Share on Alert
03 Sep 2023	Beta Drugs	Edelweiss	1698.60	1325.00	999.95 (69.87%)	Target met	Buy	pdf post cache	Broker Report Beta Drugs \| The CUB Series Edelweiss Beta Drugs (BETADR) is one of the leading players in the domestic oncology space and ranks among the top 10 in the cytotoxic market. pdf Copy Link Share on Share on Share on Share on Alert
24 Mar 2023	Beta Drugs	Edelweiss	1698.60		610.00 (178.46%)	Pre-Bonus/ Split	Not Rated	pdf post cache	Broker Report Beta Drugs \| Plant Visit Note Edelweiss We visited Beta Drugs' (BETADR) formulation facilities located at Baddi and Mohali (Chandigarh), which have been expanded and upgraded, and the management. pdf Copy Link Share on Share on Share on Share on Alert

48.50% Gain from 52W Low

Beta Drugs Ltd. share price target

There are 1 reports from 1 analysts covering Beta Drugs Ltd. available on trendlyne.com.

Beta Drugs | H1FY25 Result Update

Beta Drugs Ltd | H2FY24 Result Update

Beta Drugs | The CUB Series

Beta Drugs | Plant Visit Note

Advisor Screeners